Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Status:
Recruiting
Trial end date:
2024-06-15
Target enrollment:
Participant gender:
Summary
Xanamem is being developed as a potential treatment for symptomatic, early stages of
Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™ in
treating patients with cognitive and depressive symptoms. Trial participants will be
randomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in a
double-blinded fashion.